cheqfx
Advertisement · 728×90
‹ All stocks
OBIO

Orchestra BioMed Holdings

OBIO · NASDAQ · Healthcare
$6.07
▼ $6.07 (-5.18%)
$5.88 $5.99 $6.11 $6.23 $6.07 Sep 2026 Sep 2026 Oct 2026
Day range
$6.02 – $6.41
Year range
$2.50 – $6.50
Open
$6.40
Previous close
—
Market cap
$363.40M
Volume (24h)
$139.6K
Volume (52w)
$847.37K
Performance
7D
▲ 3.04%
1M
▲ 22.60%
3M
▲ 48.75%
6M
▲ 43.13%
1Y
▲ 126.45%
YTD
▲ 40.81%
3Y
▼ -41.48%
5Y
▼ -38.14%
All-time
▼ -46.76%
Key statistics
P/E ratio
-6.13
EPS (TTM)
$-0.99
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
59.9M
About Orchestra BioMed Holdings

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Visit website
Country: United States of America
More in Healthcare